

## LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A compound ~~8 to 80~~15 to 30 nucleobases in length targeted to ~~at least a portion of~~ a nucleic acid molecule encoding apolipoprotein(a), wherein said compound is at least ~~70%~~ 80% complementary to nucleotides 12380-13493 as set forth in SEQ ID NO: 4 ~~said portion of said nucleic acid molecule encoding apolipoprotein(a), and wherein said compound is selected from the group consisting of SEQ ID NOs: 85-96.~~

2. (Original) The compound of claim 1 comprising an oligonucleotide.

3. (Original) The compound of claim 2 comprising an antisense oligonucleotide.

4. (Original) The compound of claim 1 comprising an DNA oligonucleotide.

5. (Original) The compound of claim 4 comprising an RNA oligonucleotide.

6. (Original) The compound of claim 4 comprising a chimeric oligonucleotide.

7. (Original) The compound of claim 2 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.

8. (Original) The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.

9. (Original) The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.

10. (Original) The compound of claim 1 having at least one phosphorothioate internucleoside linkage.

11. (Original) The compound of claim 1 having at least one 5-methylcytosine.

12-16 (Canceled)

17. (Original) The antisense compound of claim 1 which is single-stranded.

18-25 (Canceled)

26. (Original) A method of inhibiting the expression of apolipoprotein(a) in a cell or tissue comprising contacting said cell or tissue with the compound of claim 1 so that expression of apolipoprotein(a) is inhibited.

27-31 (Canceled)

32. (Original) A method of treating an animal having a disease or condition associated with apolipoprotein(a) comprising

selecting an animal having a disease or condition treatable by the inhibition of apolipoprotein(a), and

administering to said animal a therapeutically ~~or prophylactically~~ effective amount of the compound of claim 1 ~~or claim 18~~ so that expression of apolipoprotein(a) is inhibited.

33. (Original) The method of claim 32 wherein the disease or condition is a cardiovascular disease, atherosclerosis, hypercholesterolemia, coronary artery disease, or any combination thereof.

34-49 (Canceled)

50. (New) The compound of claim 1, wherein the compound comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, and 95.

51. (New) The method of claim 32, wherein serum apolipoprotein(a) is reduced in said animal.